CN Bio Stock (CNBI)

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.